Interventions for reducing inflammation in familial Mediterranean fever

Yin, Xi; Tian, Fang; Wu, Bin; Xu, Ting

doi:10.1002/14651858.cd010893.pub4

Cited by 9 publications

(4 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to treatment for FMF, there are limited RCTs assessing interventions for patients with FMF in the most recent Cochrane Database [10]. Based on the evidence, daily colchicine may reduce the number of attacks.…”

Section: Discussionmentioning

confidence: 99%

A patient with familial Mediterranean fever mimicking diarrhea-dominant irritable bowel syndrome who successfully responded to treatment with colchicine: a case report

et al. 2022

View full text Add to dashboard Cite

Background Irritable bowel syndrome is a functional gastrointestinal disease. Visceral hypersensitivity is the most important pathophysiology in irritable bowel syndrome. Currently, diagnosis of irritable bowel syndrome is based on symptoms and exclusion of other organic diseases. Although the diagnosis of irritable bowel syndrome can be made based on the Rome IV criteria, one may speculate that complete exclusion of other organic diseases is not so easy, especially in cases uncontrolled with standard therapies. Case presentation We present herein a case of familial Mediterranean fever in a young Japanese patient who had been suffering from an irritable bowel syndrome-like clinical course. A 25-year-old Japanese male had been diagnosed as having diarrhea-predominant irritable bowel syndrome 5 years earlier. Unfortunately, standard therapies failed to improve irritable bowel syndrome symptoms. After careful medical history-taking, we understood that he had also experienced periodic fever since 10 years ago. Although no mutation was identified in the Mediterranean fever gene, not only periodic fever but abdominal symptoms improved completely after colchicine administration. He was therefore diagnosed as having familial Mediterranean fever and that the abdominal symptoms may be related to the disease. Conclusions Familial Mediterranean fever should be considered as a cause of irritable bowel syndrome-like symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

A patient with familial Mediterranean fever mimicking diarrhea-dominant irritable bowel syndrome who successfully responded to treatment with colchicine: a case report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, the mechanism of colchicine for treatment of familial Mediterranean fever is still unclear. Evidences show that colchicine could disrupt the assembly of inflammasome in neutrophils and monocytes, and consequently inhibit interleukin-1β activating [ 14 ]. Recently, colchicine was proposed as a potentially pharmacological agent in cardiovascular diseases depending on its anti-inflammatory property [ 10 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Colchicine protects against the development of experimental abdominal aortic aneurysm

Zhao,

Shen,

Chen

et al. 2023

Clinical Science

View full text Add to dashboard Cite

Abdominal aortic aneurysm (AAA) is characterized by at least 1.5-fold enlargement of the infrarenal aorta, a ruptured AAA is life-threatening. Colchicine is a medicine used to treat gout and familial Mediterranean fever, and recently it was approved to reduce the risk of cardiovascular events in adult patients with established atherosclerotic disease. With an AAA mice model created by treatment with porcine pancreatic elastase (PPE) and beta aminopropionitrile (BAPN), this work was designed to explore whether colchicine could protect against the development of AAA. Here, we showed that colchicine could limit AAA formation, as evidenced by the decreased total aortic weight per body weight, AAA incidence, maximal abdominal aortic diameter and collagen deposition. We also found that colchicine could prevent the phenotypic switching of vascular smooth muscle cells from a contractile to synthetic state during AAA. In addition, it was demonstrated that colchicine was able to reduce vascular inflammation, oxidative stress, cell pyroptosis and immune cells infiltration to the aortic wall in the AAA mice model. Finally, it was proved that the protective action of colchicine against AAA formation was mainly mediated by preventing immune cells infiltration to the aortic wall. In summary, our findings demonstrated that colchicine could protect against the development of experimental AAA, providing a potential therapeutic strategy for AAA intervention in the clinic.

show abstract

“…CRP is a biomarker most commonly used in the evaluation of febrile children to assess the presence and severity of inflammation [ 11 , 12 ]. It is important to note that CRP levels alone cannot diagnose a specific condition but are used in conjunction with other clinical assessments and laboratory tests to help determine the cause of fever and guide appropriate management [ 13 , 14 ]. Elevated CRP levels indicate the activation of the acute-phase response, which is typically associated with infectious or inflammatory conditions [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Hemoglobin and Its Z Score Reference Intervals in Febrile Children: A Cohort Study of 98,572 Febrile Children

Cheng,

Hsu,

Yang

et al. 2023

Children

View full text Add to dashboard Cite

Objectives: Febrile disease and age of children were associated with a variation in hemoglobin (Hb) level. Both CRP and Hb serve as laboratory markers that offer valuable insights into a patient’s health, particularly in relation to inflammation and specific medical conditions. Although a direct correlation between CRP and Hb levels is not established, the relationship between these markers has garnered academic attention and investigation. This study aimed to determine updated reference ranges for Hb levels for age and investigated its correlation with CRP in febrile children under the age of 18. Methods: This is a cohort study of in Chang Gung Memorial Hospitals conducted from January 2010 to December 2019. Blood samples were collected from 98,572 febrile children who were or had been admitted in the pediatric emergency department. The parameters of individuals were presented as the mean ± standard deviation or 2.5th and 97.5th percentiles. We also determined the variation of Hb and Z score of Hb between CRP levels in febrile children. Result: We observed that the Hb levels were the highest immediately after birth and subsequently underwent a rapid decline, reaching their lowest point at around 1–2 months of age, and followed by a steady increment in Hb levels throughout childhood and adolescence. In addition, there was a significant and wide variation in Hb levels during the infant period. It revealed a significant association between higher CRP levels and lower Hb levels or a more negative Z score of Hb across all age subgroups. Moreover, in patients with bacteremia, CRP levels were higher, Hb concentrations were lower, and Z scores of Hb were also lower compared to the non-bacteremia group. Furthermore, the bacteremia group exhibited a more substantial negative correlation between CRP levels and a Z score of Hb (r = −0.41, p < 0.001) compared to the non-bacteremia group (r = −0.115, p < 0.049). Conclusion: The study findings revealed that the Hb references varied depending on the age of the children and their CRP levels. In addition, we established new reference values for Hb and its Z scores and explore their relationship with CRP. It provides valuable insights into the Hb status and its potential association with inflammation in febrile pediatric patients.

show abstract

Interventions for reducing inflammation in familial Mediterranean fever

Cited by 9 publications

References 88 publications

A patient with familial Mediterranean fever mimicking diarrhea-dominant irritable bowel syndrome who successfully responded to treatment with colchicine: a case report

A patient with familial Mediterranean fever mimicking diarrhea-dominant irritable bowel syndrome who successfully responded to treatment with colchicine: a case report

Colchicine protects against the development of experimental abdominal aortic aneurysm

Hemoglobin and Its Z Score Reference Intervals in Febrile Children: A Cohort Study of 98,572 Febrile Children

Contact Info

Product

Resources

About